These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 24677712

  • 1. Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3.
    Østoft SH, Bagger JI, Hansen T, Pedersen O, Holst JJ, Knop FK, Vilsbøll T.
    Diabetes; 2014 Aug; 63(8):2838-44. PubMed ID: 24677712
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes.
    Marathe CS, Rayner CK, Bound M, Checklin H, Standfield S, Wishart J, Lange K, Jones KL, Horowitz M.
    Diabetes; 2014 Aug; 63(8):2668-75. PubMed ID: 24696447
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mutations in GCK and HNF-1alpha explain the majority of cases with clinical diagnosis of MODY in Spain.
    Estalella I, Rica I, Perez de Nanclares G, Bilbao JR, Vazquez JA, San Pedro JI, Busturia MA, Castaño L, Spanish MODY Group.
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):538-46. PubMed ID: 17573900
    [Abstract] [Full Text] [Related]

  • 7. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia.
    Junker AE, Gluud L, Holst JJ, Knop FK, Vilsbøll T.
    J Intern Med; 2016 May; 279(5):485-93. PubMed ID: 26728692
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G, Natalicchio A, Marchetti P.
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Circulating ghrelin level is higher in HNF1A-MODY and GCK-MODY than in polygenic forms of diabetes mellitus.
    Nowak N, Hohendorff J, Solecka I, Szopa M, Skupien J, Kiec-Wilk B, Mlynarski W, Malecki MT.
    Endocrine; 2015 Dec; 50(3):643-9. PubMed ID: 25987348
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impaired regulation of the incretin effect in patients with type 2 diabetes.
    Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):737-45. PubMed ID: 21252240
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.
    Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA.
    Diabetologia; 2007 Apr; 50(4):806-13. PubMed ID: 17334652
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.